Skip to main content

Can-Fite BioPharma Ltd.

corporate_fare Company Profile

Can-Fite BioPharma Ltd.

CANF·NYSE·Life Sciences·CIK 0001536196

Can-Fite BioPharma Ltd. is an advanced clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. Its platform technology uses the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells and has low expression in normal cells, suggesting the receptor could be a specific target for pharmacological intervention. The company's pipeline consists of synthetic, highly specific agonists and allosteric modulators targeting the A3AR. The pipeline is based on research by Dr. Pnina Fishman, who investigated the clinical observation that tumor metastasis can be found in most body tissues but is rarely found in muscle tissue, which constitutes approximately 60% of human body weight. Her research revealed that one reason striated muscle tissue is resistant to tumor metastasis is that muscle cells release small molecules that bind with high selectivity to the A3AR. She also discovered that A3ARs have significant expression in tumor and inflammatory cells, whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators in the company's pipeline bind with high selectivity and affinity to A3ARs and initiate downstream signal transduction pathways resulting in apoptosis, or programmed cell death, of tumor and inflammatory cells, and in the inhibition of inflammatory cytokines. Cytokines are proteins produced by cells that interact with cells of the immune system to regulate the body's response to disease and infection; overproduction or inappropriate production of certain cytokines can result in disease. The product candidates also induce production of positive cytokines such as granulocyte colony stimulating factor (G-CSF) and adiponectin, which are responsible for the chemo-protective and liver-protective effects of the drugs on the liver. The product candidates CF101, CF102 and CF602 are being developed to treat oncological and inflammatory diseases, as well as erectile dysfunction.

Can-Fite BioPharma Ltd. (NYSE:CANF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for CANF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Recent SEC coverage for CANF spans 6-K.

Recent high-impact activity:

  • Can-Fite Completes Dosing in Phase III Psoriasis Cohort; Interim Data Due Q1 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
405K
Net Income
-9.83M
Diluted EPS
-5.97
Op. Cash Flow
-8.95M
Free Cash Flow
-8.95M
Operating Income
-9.95M
Cash & Equivalents
5.53M
Debt / Equity
0.00×
Net Margin
-24.27×
Shares Outstanding
2.62M sh
Source: 20-F · filed 2026-03-26 · accession 0001213900-26-034447

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 31,345 shares in CANF as of the October 30, 2026 settlement, a 7.2% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 5.2% of CANF volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)31,345 shares as of October 30, 2026
Change vs prior period▼ 7.2%
Days to cover1.00 at avg daily volume of 101,449
Daily short volume (FINRA facilities)5.2% of 10,438 shares on November 20, 2026
5-day average short volume36.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

CANF files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$1.49 +1.06% today
52-week range · as of 2026-11-18 $1.42 – $12.3
Market cap
$4.64M
Volume
16.8K (0.3× avg)
3-mo avg 56.8K
Live data · 2026-11-22 12:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CANF - Latest Insights

CANF
Nov 18, 2026, 7:03 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $1.49 info
Change: -$0.065 (-4%) info
Market Cap: $4.637M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets